Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

Abstract

According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. To address the role of B in combination with rituximab (BR), we analyzed the outcome of 71 patients with relapsed/refractory disease, median age 72 years, treated with R 375 mg/m² day 1 and B days 1 and 2 (dosage ranging from 50 to 90 mg/m²). Patients had previously received a median number of 2 lines of treatment (range 1–5). Overall and major response rates were 80.2% and 74.6%. Major toxicity was grade 3/4 neutropenia occurring in 13% of courses. There was no significant association between baseline features or patients’ characteristics and response achievement. Median progression-free survival was not reached after a median follow-up of 19 months (range 3–54). None of the patients developed aggressive lymphoma or secondary myelodysplastic syndrome/acute myeloid leukemia. BR was found to be an active and well-tolerated salvage regimen leading to rapid disease control.

Keywords::

• Bendamustine
• rituximab
• Waldenström macroglobulinemia
• relapsed
• refractory
• salvage

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.